<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074139</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU040314</org_study_id>
    <secondary_id>CDR0000343609</secondary_id>
    <secondary_id>CWRU-AVEN-1103</secondary_id>
    <secondary_id>AVENTIS-XRP6976D/1001</secondary_id>
    <nct_id>NCT00074139</nct_id>
  </id_info>
  <brief_title>Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer</brief_title>
  <official_title>A Pharmacokinetic Interaction Study Of Docetaxel (Taxotere) 75 mg/mIV On The Combination Therapy Doxorubicin (50 mg/m) And Cyclophosphamide (50 mg/m) In The Treatment Of Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin, and cyclophosphamide,&#xD;
      use different ways to stop tumor cells from dividing so they stop growing or die. Combining&#xD;
      more than one drug and giving them at different times, may kill more tumor cells. It is not&#xD;
      yet known which combination chemotherapy regimen is more effective for breast cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase I trial to compare the effectiveness of two regimens of docetaxel&#xD;
      combined with doxorubicin and cyclophosphamide in treating women who have advanced breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of docetaxel, doxorubicin, and cyclophosphamide in&#xD;
           women with advanced breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the pharmacokinetic profile of this regimen in these patients vs the historical&#xD;
           pharmacokinetic profile of docetaxel.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, crossover, multicenter study. Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive doxorubicin IV over 15 minutes and cyclophosphamide IV over 15&#xD;
           minutes on day 1 followed by doxorubicin IV over 15 minutes, cyclophosphamide IV over 15&#xD;
           minutes, and docetaxel IV over 1 hour on day 22.&#xD;
&#xD;
        -  Arm II: Patients receive doxorubicin IV over 15 minutes, cyclophosphamide IV over 15&#xD;
           minutes, and docetaxel IV over 1 hour on day 1 followed by doxorubicin IV over 15&#xD;
           minutes and cyclophosphamide IV over 15 minutes on day 22.&#xD;
&#xD;
      Treatment in both arms continues in the absence of disease progression or unacceptable&#xD;
      toxicity. Patients may receive additional therapy at the discretion of the treating&#xD;
      physician.&#xD;
&#xD;
      Patients are followed at 3-4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients (12 per treatment arm) will be accrued for this&#xD;
      study within 7 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patients were enrolled&#xD;
  </why_stopped>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced breast cancer&#xD;
&#xD;
               -  Adjuvant setting for high-risk disease allowed&#xD;
&#xD;
          -  No symptomatic evidence or history of brain metastases&#xD;
&#xD;
          -  No leptomeningeal metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 69&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN (1.5 times ULN if alkaline phosphatase&#xD;
             greater than 2.5 times ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF or shortening fraction greater than lower limit of normal by MUGA or&#xD;
             echocardiography&#xD;
&#xD;
          -  Cardiac function normal&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No high-risk uncontrolled arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective nonhormonal contraception&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No active peptic ulcer&#xD;
&#xD;
          -  No unstable diabetes mellitus&#xD;
&#xD;
          -  No other serious illness or medical condition&#xD;
&#xD;
          -  No contraindication to corticosteroids&#xD;
&#xD;
          -  No pre-existing grade 2 or greater motor or sensory neurotoxicity&#xD;
&#xD;
          -  No psychological, social, familial, or geographical reason that would preclude study&#xD;
             follow-up&#xD;
&#xD;
          -  No history of significant neurologic or psychiatric disorder (e.g., psychotic&#xD;
             disorder, dementia, or seizures) that would preclude understanding and giving informed&#xD;
             consent&#xD;
&#xD;
          -  No other neoplasm within the past 10 years except curatively treated nonmelanoma skin&#xD;
             cancer, carcinoma in situ of the cervix, ipsilateral ductal carcinoma in situ of the&#xD;
             breast, or lobular carcinoma in situ of the breast&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 6 months since prior anthracycline or taxoid (e.g., paclitaxel or docetaxel)&#xD;
             therapy&#xD;
&#xD;
          -  No prior cumulative anthracycline dose greater than 240 mg/m^2&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent corticosteroid treatment allowed provided treatment was initiated more than&#xD;
             6 months before study entry and at a dose of less than 20 mg of methylprednisolone or&#xD;
             equivalent&#xD;
&#xD;
          -  No concurrent ovarian hormonal replacement therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 2 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior participation in another clinical trial with any&#xD;
             investigational drug or device&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
&#xD;
          -  No other concurrent systemic anticancer therapy&#xD;
&#xD;
          -  No concurrent aminoglycoside antibiotics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth A. Overmoyer, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

